172 related articles for article (PubMed ID: 18421709)
1. C-erbB-2 expression and prognostic significance in osteosarcoma.
Yalçin B; Gedikoğlu G; Kutluk T; Varan A; Akyüz C; Büyükpamukçu M
Pediatr Blood Cancer; 2008 Aug; 51(2):222-7. PubMed ID: 18421709
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of P-glycoprotein, HER-2/ErbB-2, p53, and Bcl-2 in primary tumor and metachronous lung metastases in patients with high-grade osteosarcoma.
Ferrari S; Bertoni F; Zanella L; Setola E; Bacchini P; Alberghini M; Versari M; Bacci G
Cancer; 2004 May; 100(9):1936-42. PubMed ID: 15112275
[TBL] [Abstract][Full Text] [Related]
3. ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma.
Onda M; Matsuda S; Higaki S; Iijima T; Fukushima J; Yokokura A; Kojima T; Horiuchi H; Kurokawa T; Yamamoto T
Cancer; 1996 Jan; 77(1):71-8. PubMed ID: 8630943
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of ER, PR, Ki67, c-erbB-2, and p53 in endometrial carcinoma.
Suthipintawong C; Wejaranayang C; Vipupinyo C
J Med Assoc Thai; 2008 Dec; 91(12):1779-84. PubMed ID: 19133508
[TBL] [Abstract][Full Text] [Related]
5. Metastatic osteosarcoma at diagnosis: prognostic factors and long-term outcome--the French pediatric experience.
Mialou V; Philip T; Kalifa C; Perol D; Gentet JC; Marec-Berard P; Pacquement H; Chastagner P; Defaschelles AS; Hartmann O
Cancer; 2005 Sep; 104(5):1100-9. PubMed ID: 16015627
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution.
Bacci G; Longhi A; Versari M; Mercuri M; Briccoli A; Picci P
Cancer; 2006 Mar; 106(5):1154-61. PubMed ID: 16421923
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of immunohistochemical expression of ezrin in non-metastatic high-grade osteosarcoma.
Ferrari S; Zanella L; Alberghini M; Palmerini E; Staals E; Bacchini P
Pediatr Blood Cancer; 2008 Apr; 50(4):752-6. PubMed ID: 17886294
[TBL] [Abstract][Full Text] [Related]
8. C-erbB-2 oncoprotein expression in operable non-small cell lung cancer.
Giatromanolaki A; Gorgoulis V; Chetty R; Koukourakis MI; Whitehouse R; Kittas C; Veslemes M; Gatter KC; Iordanoglou I
Anticancer Res; 1996; 16(2):987-93. PubMed ID: 8687165
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathologic analysis of HER-2/neu immunoexpression among various histologic subtypes and grades of osteosarcoma.
Kilpatrick SE; Geisinger KR; King TS; Sciarrotta J; Ward WG; Gold SH; Bos GD
Mod Pathol; 2001 Dec; 14(12):1277-83. PubMed ID: 11743051
[TBL] [Abstract][Full Text] [Related]
10. [Expression level of c-erbB-2 protein correlates with the prognosis of patients with colorectal cancer].
Zhou Z; Wan D; Zhang C
Zhonghua Zhong Liu Za Zhi; 2001 Mar; 23(2):139-41. PubMed ID: 11783020
[TBL] [Abstract][Full Text] [Related]
11. P-glycoprotein expression in osteosarcoma: a basis for risk-adapted adjuvant chemotherapy.
Baldini N; Scotlandi K; Serra M; Picci P; Bacci G; Sottili S; Campanacci M
J Orthop Res; 1999 Sep; 17(5):629-32. PubMed ID: 10569469
[TBL] [Abstract][Full Text] [Related]
12. Integrated assessment of potential value of erbB-2 amplification or expression status as novel therapy target in Chinese children and adolescents with osteosarcoma.
Shang J; Bi ZG; Ji HF; Wang WB
Chin Med J (Engl); 2009 Jul; 122(13):1521-4. PubMed ID: 19719941
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of cyclin expression in human osteosarcoma.
Molendini L; Benassi MS; Magagnoli G; Merli M; Sollazzo MR; Ragazzini P; Gamberi G; Ferrari C; Balladelli A; Bacchini P; Picci P
Int J Oncol; 1998 May; 12(5):1007-11. PubMed ID: 9538120
[TBL] [Abstract][Full Text] [Related]
14. HER2 amplification and overexpression is not present in pediatric osteosarcoma: a tissue microarray study.
Somers GR; Ho M; Zielenska M; Squire JA; Thorner PS
Pediatr Dev Pathol; 2005; 8(5):525-32. PubMed ID: 16211448
[TBL] [Abstract][Full Text] [Related]
15. [Analysis of prognostic factors in osteosarcoma adult patients, a single institution experience].
Adamkova Krakorova D; Vesely K; Zambo I; Tucek S; Tomasek J; Jureckova A; Janicek P; Cerny J; Pazourek L; Ondrusek S; Selingerova I
Klin Onkol; 2012; 25(5):346-58. PubMed ID: 23102196
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of allelic imbalance at the c-kit gene locus and c-kit overexpression by immunohistochemistry in pediatric osteosarcomas.
Entz-Werlé N; Marcellin L; Gaub MP; Guerin E; Schneider A; Berard-Marec P; Kalifa C; Brugiere L; Pacquement H; Schmitt C; Tabone MD; Jeanne-Pasquier C; Terrier P; Dijoud F; Oudet P; Lutz P; Babin-Boilletot A
J Clin Oncol; 2005 Apr; 23(10):2248-55. PubMed ID: 15800315
[TBL] [Abstract][Full Text] [Related]
17. Lower level of MAPK expression is associated with anthracycline resistance and decreased survival in patients with hormone receptor negative breast cancer.
Derin D; Eralp Y; Ozluk Y; Yavuz E; Guney N; Saip P; Igci A; Ozmen V; Kücücük S; Aslay I; Aydiner A; Topuz E
Cancer Invest; 2008 Aug; 26(7):671-9. PubMed ID: 18608215
[TBL] [Abstract][Full Text] [Related]
18. The expression of CRM1 is associated with prognosis in human osteosarcoma.
Yao Y; Dong Y; Lin F; Zhao H; Shen Z; Chen P; Sun YJ; Tang LN; Zheng SE
Oncol Rep; 2009 Jan; 21(1):229-35. PubMed ID: 19082467
[TBL] [Abstract][Full Text] [Related]
19. Anti-angiogenic factor endostatin in osteosarcoma.
Kim HS; Lim SJ; Park YK
APMIS; 2009 Oct; 117(10):716-23. PubMed ID: 19775339
[TBL] [Abstract][Full Text] [Related]
20. Prognostic effect of pathologic fracture in localized osteosarcoma: a cohort/case controlled study at a single institute.
Kim MS; Lee SY; Lee TR; Cho WH; Song WS; Cho SH; Lee JA; Yoo JY; Jung ST; Jeon DG
J Surg Oncol; 2009 Sep; 100(3):233-9. PubMed ID: 19294672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
